Breast cancer is one of the most common
cancers worldwide with a rising incidence, and is the leading cause of
cancer-related death among females. Angiogenesis plays an important role in
breast cancer growth and
metastasis. In this study, we identify
decylubiquinone (DUb), a
coenzyme Q10 analog, as a promising anti-
breast cancer agent through suppressing
tumor-induced angiogenesis. We screened a library comprising FDA-approved drugs and found that DUb significantly inhibits blood vessel formation using in vivo chick embryo chorioallantoic membrane (CAM) and yolk sac membrane (YSM) models. DUb was further identified to inhibit angiogenesis in the rat aortic ring and
Matrigel plug assay. Moreover, DUb was found to suppress
breast cancer growth and
metastasis in the MMTV-PyMT transgenic mouse and human xenograft
tumor models. To explore whether the anticancer efficacy of DUb was directly corrected with
tumor-induced angiogenesis, the MDA-MB-231
breast cancer assay on the CAM was performed. Interestingly, DUb significantly inhibits the angiogenesis of
breast cancer on the CAM. Brain
angiogenesis inhibitor 1 (BAI1), a member of the
G protein-coupled receptor (GPCR) adhesion subfamily, has an important effect on the inhibition of angiogenesis. Further studies demonstrate that DUb suppresses the formation of tubular structures by regulating the
reactive oxygen species (ROS)/p53/BAI1 signaling pathway. These results uncover a novel finding that DUb has the potential to be an effective agent for the treatment of
breast cancer by inhibiting
tumor-induced angiogenesis.